AIVITA Biomedical nabs $25m
AIVITA Biomedical Inc, a developer of personalized vaccines for the treatment of cancer and prevention of COVID-19, has raised up to $25 million in Series B-2 financing.
AIVITA Biomedical Inc, a developer of personalized vaccines for the treatment of cancer and prevention of COVID-19, has raised up to $25 million in Series B-2 financing.
Copyright PEI Media
Not for publication, email or dissemination